Gregory J. Flesher is CEO at Novus Therapeutics, Inc. (NVUS). They have made 3 open-market trades across 2 companies since 2017, most recently 2021-12-10.
CIK 0001705287
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $1.2M since 2017, against 1 sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.